Balchem Corporation Reports Second Quarter 2024 Financial Results

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Insights

Balchem 's Q2 2024 results demonstrate a mixed performance across its business segments. The company reported overall growth, with net sales increasing by 1.2% to $234.1 million and adjusted EBITDA rising by 5.0% to a record $62.3 million.

The standout performers were the Human Nutrition & Health and Specialty Products segments. Human Nutrition & Health saw impressive growth with sales up 9.0% and record earnings from operations increasing 21.3%. This growth was primarily driven by higher sales in the minerals and nutrients business. Similarly, Specialty Products reported a 7.2% increase in sales and a 20.8% rise in earnings from operations.

However, the Animal Nutrition & Health segment faced challenges, with sales declining 19.2% and earnings from operations dropping 64.9%. This significant downturn in the animal nutrition market is a concern and warrants close monitoring.

Financially, Balchem maintains a strong position with a healthy cash flow. The company generated $45.0 million from operating activities and $38.4 million in free cash flow. This allowed for a $35.0 million repayment on their revolving debt, reducing their net debt to $202.8 million with a low leverage ratio of 0.9 times.

The launch of Optifolin+® demonstrates Balchem's commitment to innovation and expanding its product portfolio. This new offering could potentially drive future growth in the Human Nutrition & Health segment.

Overall, while the company faces headwinds in its Animal Nutrition & Health segment, the strong performance in other areas and solid financial position suggest Balchem is well-positioned to navigate current market conditions.

Balchem's Q2 2024 results offer intriguing insights into current market trends across various nutrition and health sectors. The divergent performance of the company's segments provides a snapshot of broader industry dynamics.

The Human Nutrition & Health segment's strong growth (9.0% sales increase) aligns with the growing consumer focus on health and wellness. The demand for minerals and nutrients suggests a continued trend towards preventative health measures and functional foods. The launch of Optifolin+®, a choline-enriched folate ingredient, further capitalizes on this trend, particularly addressing cellular health across all life stages.

Conversely, the Animal Nutrition & Health segment's significant decline (19.2% sales decrease) points to potential challenges in the livestock and agriculture markets. This could be due to factors such as changing consumer preferences, environmental concerns, or economic pressures on farmers.

The Specialty Products segment's growth, particularly in performance gases, might indicate increased demand in industrial or medical applications. This diversification helps balance the company's portfolio against fluctuations in other markets.

Balchem's ability to maintain profitability and even achieve record earnings in some segments, despite inflationary pressures and supply chain challenges that have affected many industries, is noteworthy. The company's focus on innovation and strategic initiatives, coupled with its strong cash flow and debt reduction, suggests a proactive approach to navigating market uncertainties.

Looking ahead, the contrasting performance across segments underscores the importance of diversification in the current market environment. Companies able to pivot and capitalize on growth areas while managing challenges in others are likely to be more resilient in the face of economic uncertainties.

07/26/2024 - 07:00 AM

MONTVALE, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal second quarter ended June 30, 2024. The Company reported quarterly net sales of $234.1 million, quarterly net earnings of $32.1 million, adjusted EBITDA^(a) of $62.3 million, and free cash flow^(a)of $38.4 million.

Ted Harris, Chairman, President and CEO of Balchem said, "We delivered solid second quarter financials with record earnings from operations and adjusted EBITDA. I am particularly pleased with the excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings growth.”

Second Quarter 2024 Financial Highlights:

Net sales were $234.1 million, an increase of 1.2% compared to the prior year quarter.
Adjusted EBITDA was a record $62.3 million, an increase of 5.0% from the prior year quarter.
GAAP net earnings were $32.1 million, an increase of 6.5% from the prior year quarter.
GAAP earnings per share of $0.98 compared to $0.93 in the prior year quarter and record adjusted earnings per share^(a) of $1.09 compared to $1.06 in the prior year quarter.
Cash flows from operations were $45.0 million for the second quarter of 2024, with quarterly free cash flow^(a)of $38.4 million.
Strong sales growth and record earnings from operations in both our Human Nutrition and Health and Specialty Product segments.

Recent Highlights:

On May 20th, Balchem launched a new product, Optifolin+^®, which is a patented, choline-enriched, bioactive, reduced folate ingredient that supports cellular health at all stages of life. Optifolin+^® is biologically active, which means that it is readily available for transport and use in the human body and tissues, making Optifolin+^® an excellent choice to meet Vitamin B9 recommended requirements.
Strong cash flows in the second quarter enabled us to make repayments on our revolving debt of $35.0 million, bringing our net debt to $202.8 million, with an overall leverage ratio on a net debt basis of 0.9 times.

Mr. Harris said, "I am excited about the recent launch of Optifolin+^® and our continued focus on bringing innovative solutions for the health and nutritional needs of the world. Optifolin+^®adds to our already strong Minerals and Nutrients portfolio that includes leading brands such as VitaCholine^®, K2Vital^®, Albion^® Minerals, and OptiMSM^®.”

Mr. Harris continued, "We continue to make good progress on our strategic initiatives while delivering solid financial results. I am very pleased with our performance in the first half of 2024 and look forward to the remainder of the year."

Results for Period Ended June 30, 2024 (unaudited) (Dollars in thousands, except per share data)

	Three Months Ended June 30,				Six Months Ended June 30,
		2024		2023		2024		2023
Net sales	$	234,081	$	231,252	$	473,740	$	463,792
Gross margin		82,994		77,349		164,508		150,519
Operating expenses		37,197		34,513		77,035		73,275
Earnings from operations		45,797		42,836		87,473		77,244
Interest and other expenses		4,571		4,436		9,397		9,725
Earnings before income tax expense		41,226		38,400		78,076		67,519
Income tax expense		9,157		8,290		17,021		14,699
Net earnings	$	32,069	$	30,110	$	61,055	$	52,820

Diluted net earnings per common share	$	0.98	$	0.93	$	1.87	$	1.63

Adjusted EBITDA^(a)	$	62,270	$	59,317	$	123,136	$	115,674
Adjusted net earnings^(a)	$	35,577	$	34,441	$	69,161	$	65,022
Adjusted net earnings per common share^(a)	$	1.09	$	1.06	$	2.12	$	2.01

Shares used in the calculations of diluted and adjusted net earnings per common share		32,649		32,434		32,638		32,424

^(a)	See “Non-GAAP Financial Information” for a reconciliations of GAAP and non-GAAP financial measures.

Financial Results for the Second Quarter of 2024:

The Human Nutrition & Health segment generated sales of $147.9 million, an increase of $12.3 million, or 9.0%, compared to the prior year quarter. The increase was primarily driven by higher sales within the minerals and nutrients business. Record earnings from operations for this segment of $33.4 million increased $5.9 million, or 21.3%, compared to $27.5 million in the prior year quarter, primarily due to the aforementioned higher sales, a favorable mix, and certain lower manufacturing input costs, partially offset by higher operating expenses. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations^(a) for this segment were $37.4 million, compared to $31.8 million in the prior year quarter, an increase of 17.6%.

The Animal Nutrition & Health segment generated quarterly sales of $49.6 million, a decrease of $11.8 million, or 19.2%, compared to the prior year quarter. The decrease was driven by lower sales in both the monogastric and ruminant species markets. Second quarter earnings from operations for this segment of $2.7 million decreased $5.0 million, or 64.9%, compared to $7.7 million in the prior year quarter, primarily due to the aforementioned lower sales, partially offset by certain lower manufacturing input costs. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $3.0 million compared to $7.6 million in the prior year quarter, a decrease of 61.1%.

The Specialty Products segment generated quarterly sales of $35.1 million, an increase of $2.4 million, or 7.2%, compared to the prior year quarter, primarily due to higher sales in the performance gases business. Earnings from operations for this segment were a record $11.2 million, compared to $9.3 million in the prior year comparable quarter, an increase of $1.9 million, or 20.8%, primarily driven by the aforementioned higher sales and certain lower manufacturing input costs, partially offset by higher operating expenses. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $12.3 million, compared to $10.5 million in the prior year quarter, an increase of 17.1%.

Record quarterly consolidated gross margin of $83.0 million increased by $5.6 million, or 7.3%, compared to $77.3 million for the prior year comparable period. Gross margin as a percentage of sales was 35.5% as compared to 33.4% in the prior year period, an increase of 210 basis points, primarily due to a favorable mix and decreases in certain manufacturing input costs. Operating expenses of $37.2 million for the quarter increased $2.7 million from the prior year comparable quarter, primarily due to the impact of favorable adjustments to transaction costs in the prior year and higher charges related to outside services, partially offset by the impact of restructuring-related impairment charges in the prior year. Excluding non-cash operating expenses associated with amortization of intangible assets of $4.6 million, operating expenses were $32.6 million, or 13.9% of sales.

Interest expense was $4.2 million and $5.2 million in the second quarters of 2024 and 2023, respectively. The decrease in interest expense was primarily due to lower outstanding borrowings, partially offset by higher interest rates. Our effective tax rates for the three months ended June 30, 2024 and 2023 were 22.2% and 21.6%, respectively. The higher effective tax rate was primarily due to lower tax benefits from stock-based compensation and certain higher state taxes, partially offset by certain lower foreign taxes.

Second quarter cash flows provided by operating activities were $45.0 million and free cash flow was $38.4 million. The $206.8 million of net working capital on June 30, 2024 included a cash balance of $63.7 million. Significant cash payments during the quarter included repayments on the revolving loan of $35.0 million, income taxes paid of $18.2 million, and capital expenditures and intangible assets acquired of $6.9 million.

Ted Harris said, “The Balchem team delivered solid second quarter financial results, once again highlighting the resilience of our business model. Two of our three reporting segments are performing very well, with both our Human Nutrition and Health segment and Specialty Products segment delivering record earnings from operations, which are more than offsetting the challenges we are experiencing in our Animal Nutrition and Health segment. We are well positioned in the markets we serve and remain confident in the long-term growth outlook for our company as we continue to focus on progressing our strategic growth initiatives in 2024 and beyond.”

Quarterly Conference Call

A quarterly conference call will be held on Friday, July 26, 2024, at 11:00 AM Eastern Time (ET) to review second quarter 2024 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO will host the call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five minutes prior to the scheduled start time of the conference call. The conference call will be available for replay three hours after the conclusion of the call through end of day Friday, August 9, 2024. To access the replay of the conference call, dial 1-877-660-6853 (local dial-in 1-201-612-7415), and use conference ID #13747779.

Segment Information

Balchem Corporation reports three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".

Forward-Looking Statements

This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," “likely,” "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this release. Factors that might cause differences from the forward-looking statements include those referred to or identified in Balchem’s Annual Report on Form 10-K for the year ended December 31, 2023 and other factors that may be identified elsewhere in this release or in our other SEC filings. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)

Selected Financial Data (unaudited)
($ in 000’s)

Business Segment Net Sales:	Three Months Ended June 30,				Six Months Ended June 30,
		2024		2023		2024		2023
Human Nutrition & Health	$	147,928	$	135,669	$	300,672	$	268,322
Animal Nutrition & Health		49,557		61,329		103,478		126,218
Specialty Products		35,094		32,726		66,707		64,957
Other and Unallocated ^(b)		1,502		1,528		2,883		4,295
Total	$	234,081	$	231,252	$	473,740	$	463,792

Business Segment Earnings Before Income Taxes:	Three Months Ended June 30,						Six Months Ended June 30,
		2024			2023			2024			2023
Human Nutrition & Health	$	33,367		$	27,499		$	66,624		$	45,934
Animal Nutrition & Health		2,693			7,662			4,753			17,160
Specialty Products		11,228			9,298			19,427			17,244
Other and Unallocated ^(b)		(1,491	)		(1,623	)		(3,331	)		(3,094	)
Interest and other expenses		(4,571	)		(4,436	)		(9,397	)		(9,725	)
Total	$	41,226		$	38,400		$	78,076		$	67,519

^(b) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs of $132 and $572 for the three and six months ended June 30, 2024, respectively, and $651 and $1,216 for the three and six months ended June 30, 2023, respectively, and (ii) Unallocated amortization expense of $0 and $0 for the three and six months ended June 30, 2024, respectively, and $0 and $312 for the three and six months ended June 30, 2023, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.

Selected Balance Sheet Items
(Dollars in thousands)	June 30, 2024		December 31, 2023
	(unaudited)

Cash and Cash Equivalents	$	63,738	$	64,447
Accounts Receivable, net		123,400		125,284
Inventories		117,099		109,521
Other Current Assets		15,919		14,990
Total Current Assets		320,156		314,242

Property, Plant & Equipment, net		272,539		276,039
Goodwill		770,026		778,907
Intangible Assets with Finite Lives, net		176,102		191,212
Right of Use Assets		18,445		19,864
Other Assets		17,698		16,947
Total Non-current Assets		1,254,810		1,282,969

Total Assets	$	1,574,966	$	1,597,211

Current Liabilities	$	113,322	$	148,491
Revolving Loan		266,569		309,569
Deferred Income Taxes		49,956		52,046
Other Long-Term Obligations		32,755		33,121
Total Liabilities		462,602		543,227

Stockholders' Equity		1,112,364		1,053,984

Total Liabilities and Stockholders' Equity	$	1,574,966	$	1,597,211

Balchem Corporation Condensed Consolidated Statements of Cash Flows (Dollars in thousands)

(unaudited)
	Six Months Ended June 30,
		2024			2023
Cash flows from operating activities:
Net earnings	$	61,055		$	52,820
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization		26,174			27,074
Stock compensation expense		8,636			8,518
Other adjustments		(1,106	)		(2,647	)
Changes in assets and liabilities		(16,379	)		(15,936	)
Net cash provided by operating activities		78,380			69,829

Cash flows from investing activities:
Capital expenditures and intangible assets acquired		(13,788	)		(17,880	)
Cash paid for acquisitions, net of cash acquired		—			(341	)
Proceeds from the sale of assets		272			1,881
Proceeds from settlement of net investment hedge		—			2,740
Investment in affiliates		(80	)		(72	)
Net cash used in investing activities		(13,596	)		(13,672	)

Cash flows from financing activities:
Proceeds from revolving loan		26,000			13,000
Principal payments on revolving loan		(69,000	)		(48,000	)
Principal payments on finance lease		(111	)		(110	)
Proceeds from stock options exercised		9,682			3,826
Dividends paid		(25,568	)		(22,869	)
Purchase of common stock		(5,213	)		(3,924	)
Net cash used in financing activities		(64,210	)		(58,077	)

Effect of exchange rate changes on cash		(1,283	)		2,216

(Decrease) increase in cash and cash equivalents		(709	)		296

Cash and cash equivalents, beginning of period		64,447			66,560
Cash and cash equivalents, end of period	$	63,738		$	66,856

Non-GAAP Financial Information

In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted per diluted share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, and free cash flow. The non-GAAP financial measures disclosed by the company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.

Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

Table 1

Reconciliation of Non-GAAP Measures to GAAP (Dollars in thousands, except per share data)

(unaudited)
	Three Months Ended June 30,						Six Months Ended June 30,
		2024			2023			2024			2023
Reconciliation of adjusted gross margin
GAAP gross margin	$	82,994		$	77,349		$	164,508		$	150,519
Inventory valuation adjustment ⁽¹⁾		—			217			—			1,419
Amortization of intangible assets and finance lease ⁽²⁾		707			662			1,411			1,343
Restructuring costs ⁽³⁾		—			120			—			120
Adjusted gross margin	$	83,701		$	78,348		$	165,919		$	153,401

Reconciliation of adjusted earnings from operations
GAAP earnings from operations	$	45,797		$	42,836		$	87,473		$	77,244
Inventory valuation adjustment ⁽¹⁾		—			217			—			1,419
Amortization of intangible assets and finance lease ⁽²⁾		5,303			6,952			11,705			14,302
Transaction and integration costs ⁽⁴⁾		41			(7,349	)		481			(5,184	)
Restructuring costs ⁽³⁾		—			6,266			—			6,266
Nonqualified deferred compensation plan expense ⁽⁵⁾		113			244			516			481
Adjusted earnings from operations	$	51,254		$	49,166		$	100,175		$	94,528

Reconciliation of adjusted net earnings
GAAP net earnings	$	32,069		$	30,110		$	61,055		$	52,820
Inventory valuation adjustment ⁽¹⁾		—			217			—			1,419
Amortization of intangible assets and finance lease ⁽²⁾		5,375			7,024			11,849			14,446
Transaction and integration costs ⁽⁴⁾		41			(7,349	)		481			(5,184	)
Restructuring costs ⁽³⁾		—			6,266			—			6,266
Income tax adjustment ⁽⁶⁾		(1,908	)		(1,827	)		(4,224	)		(4,745	)
Adjusted net earnings	$	35,577		$	34,441		$	69,161		$	65,022

Adjusted net earnings per common share - diluted	$	1.09		$	1.06		$	2.12		$	2.01

Table 2
(unaudited)

Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA (Dollars in thousands)

	Three Months Ended June 30,					Six Months Ended June 30,
		2024		2023			2024		2023
Net earnings - as reported	$	32,069	$	30,110		$	61,055	$	52,820
Add back:
Provision for income taxes		9,157		8,290			17,021		14,699
Interest and other expenses		4,571		4,436			9,397		9,725
Depreciation and amortization		12,433		13,355			26,030		26,930
EBITDA		58,230		56,191			113,503		104,174
Add back certain items:
Non-cash compensation expense related to equity awards		3,886		3,748			8,636		8,518
Inventory valuation adjustment ⁽¹⁾		—		217			—		1,419
Transaction and integration costs ⁽⁴⁾		41		(7,349	)		481		(5,184	)
Restructuring costs ⁽³⁾		—		6,266			—		6,266
Nonqualified deferred compensation plan expense ⁽⁵⁾		113		244			516		481
Adjusted EBITDA	$	62,270	$	59,317		$	123,136	$	115,674

Table 3
(unaudited)

Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate (Dollars in thousands)

	Three Months Ended June 30,
		2024	Effective Tax Rate			2023	Effective Tax Rate
GAAP Income Tax Expense	$	9,157	22.2	%	$	8,290	21.6	%
Impact of ASU 2016-09 ⁽⁷⁾		620				448
Adjusted Income Tax Expense	$	9,777	23.7	%	$	8,738	22.8	%

	Six Months Ended June 30,
		2024	Effective Tax Rate			2023	Effective Tax Rate
GAAP Income Tax Expense	$	17,021	21.8	%	$	14,699	21.8	%
Impact of ASU 2016-09 ⁽⁷⁾		1,327				844
Adjusted Income Tax Expense	$	18,348	23.5	%	$	15,543	23.0	%

Table 4

(unaudited)

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Dollars in thousands)

	Three Months Ended June 30,						Six Months Ended June 30,
		2024			2023			2024			2023
Net cash provided by operating activities	$	44,992		$	34,991		$	78,380		$	69,829
Capital expenditures, proceeds from the sale of assets, and settlement of net investment hedge		(6,602	)		(3,280	)		(13,175	)		(12,892	)
Free cash flow	$	38,390		$	31,711		$	65,205		$	56,937

⁽¹⁾Inventory valuation adjustment: Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of inventory reflects the acquired company's cost of manufacturing plus a portion of the expected profit margin. The non-GAAP adjustment to our cost of sales excludes the expected profit margin component that is recorded under business combination accounting principles. We believe the adjustment is useful to investors as an additional means to reflect cost of sales and gross margin trends of our business.

⁽²⁾Amortization of intangible assets and finance lease: Amortization of intangible assets and finance lease consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, an intangible asset in connection with a company-wide ERP system implementation, and one finance lease. We record expense relating to the amortization of these intangibles and finance lease in our GAAP financial statements. Amortization expenses for our intangible assets and finance lease are inconsistent in amount and are significantly impacted by the timing and valuation of an acquisition. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance.

⁽³⁾Restructuring costs: Expenses related to a reorganization of the business.

⁽⁴⁾Transaction and integration costs: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.

⁽⁵⁾ Nonqualified deferred compensation plan (income) expense: Gains and losses on rabbi trust assets related to our nonqualified deferred compensation plan are recorded in other (income) expense while the offsetting increases or decreases to the deferred compensation liability are recorded within earnings from operations. The increases and decreases in the deferred compensation liability are driven by market volatility and are not a true reflection of company performance. We believe excluding these amounts from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount based on market conditions causing comparison of current and historical financial results to be difficult. Adjustments have been made to the prior period presentation to conform with the current period presentation.

⁽⁶⁾ Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate.

⁽⁷⁾Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and six months ended June 30, 2024 and 2023, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities.

FAQ

What was Balchem's (BCPC) revenue in Q2 2024?

Balchem (BCPC) reported net sales of $234.1 million in Q2 2024, representing a 1.2% increase compared to the prior year quarter.

How much did Balchem's (BCPC) earnings per share grow in Q2 2024?

Balchem's GAAP earnings per share increased to $0.98 in Q2 2024, compared to $0.93 in the prior year quarter. Adjusted earnings per share reached a record $1.09, up from $1.06 in Q2 2023.

What new product did Balchem (BCPC) launch in Q2 2024?

On May 20th, 2024, Balchem launched Optifolin+®, a patented, choline-enriched, bioactive, reduced folate ingredient that supports cellular health at all stages of life.

How did Balchem's (BCPC) Human Nutrition & Health segment perform in Q2 2024?

Balchem's Human Nutrition & Health segment generated sales of $147.9 million, a 9.0% increase year-over-year, with record earnings from operations of $33.4 million, up 21.3% compared to Q2 2023.

Balchem Corporation Reports Second Quarter 2024 Financial Results

Insights

FAQ

What was Balchem's (BCPC) revenue in Q2 2024?

How much did Balchem's (BCPC) earnings per share grow in Q2 2024?

What new product did Balchem (BCPC) launch in Q2 2024?

How did Balchem's (BCPC) Human Nutrition & Health segment perform in Q2 2024?

NASDAQ:BCPC

BCPC Rankings

BCPC Latest News

BCPC Stock Data

Trending News

Balchem Corporation Reports Second Quarter 2024 Financial Results

Insights

Financial Analyst positive

Market Research Analyst positive

FAQ

What was Balchem's (BCPC) revenue in Q2 2024?

How much did Balchem's (BCPC) earnings per share grow in Q2 2024?

What new product did Balchem (BCPC) launch in Q2 2024?

How did Balchem's (BCPC) Human Nutrition & Health segment perform in Q2 2024?

NASDAQ:BCPC

BCPC Rankings

BCPC Latest News

BCPC Stock Data